Fig. 1: Approach to liver transplantation during COVID-19. | Nature Reviews Gastroenterology & Hepatology

Fig. 1: Approach to liver transplantation during COVID-19.

From: COVID-19 and liver transplantation

Fig. 1

Epidemiological screening includes any of the following: travel or residence in a high-risk area, contact with a suspected case of coronavirus disease 2019 (COVID-19) ≤21 days before, or contact with a confirmed case of COVID-19 ≤28 days before. Clinical screening includes onset of any of the following symptoms 21 days before evaluation: fever >38 °C; malaise or flu-like symptoms; new cough; shortness of breath; unexplained abdominal pain, nausea or diarrhoea; or loss of sense of taste or smell. *Liver transplantation (LT) decision should be made with caution and at least 28 days after presumptive diagnosis of COVID-19. Figure is based on the main international transplant societies’ recommendations (such as AST and AASLD). DCD, deceased donor; LD, living donor. For further details, see Supplementary Box 1.

Back to article page